DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)

Running, not enrolling · Phase 2

Conditions studied: Breast Cancer

In brief

A randomized, Phase II trial of circulating tumor DNA-guided second line Adjuvant therapy for high Residual risk, Estrogen Receptor positive, HER-2 negative breast cancer (DARE)

Key facts

Study ID
NCT04567420
Run by
Criterium, Inc.
People needed
70
Starts
2021-02-09
Expected to finish
2028-12-31
Last updated by the study team
2026-07-08

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.